|
Apr 17
|
High Growth Tech Stocks To Watch In The US April 2025
|
|
Apr 16
|
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
|
|
Mar 27
|
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
|
|
Mar 27
|
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
|
|
Mar 26
|
Exelixis to present positive preclinical data across pipeline portfolio at AACR
|
|
Mar 26
|
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
|
|
Mar 26
|
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET
|
|
Mar 26
|
Here's Why Exelixis (EXEL) is a Strong Growth Stock
|
|
Mar 26
|
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
|
|
Mar 25
|
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
|
|
Mar 24
|
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
|
|
Mar 21
|
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
|
|
Mar 20
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Mar 19
|
Exelixis Growth Continues with Big Money Boosts
|
|
Mar 18
|
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires
|
|
Mar 13
|
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
|
|
Mar 12
|
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
|
|
Mar 12
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jan 28
|
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
|
|
Jan 27
|
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
|